Within the context of pediatric r/r B-ALL, blinatumomab is the sole FDA-approved BITE therapy and is available for use in children with CD19-positive r/r B-ALL (including Ph-positive B-ALL). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.